Aclaris TherapeuticsNASDAQ: ACRS

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.42 per share a year ago.

Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

MIRAMAR, Fla.--(BUSINESS WIRE)-- #defenseaerospace--AllClear Repair Services (“ACRS”), a wholly owned subsidiary of AllClear Aerospace & Defense (“AllClear”), has been approved by Honeywell as an authorized service center for Honeywell military APUs and mechanical components for C-130, F-15, F-16, F-18 and military derivatives of B707 platforms. The Honeywell authorized service center agreement authorizes ACRS to perform maintenance on pneumatic components, starter control valves, anti-ice valves, wheels and b.

Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.

Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago.

Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.